Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press96010.17650/1726-9776-2019-15-2-148-149RESOLUTIONРЕЗОЛЮЦИИImmunotherapy advisory council for urothelial cancerКонсультационный совет по иммунотерапии уротелиального ракаEditorialArticleРедакционнаяСтатья
Russian Federation
300620191521481490907201909072019https://oncourology.abvpress.ru/oncur/article/view/960

.

23 апреля 2019 в г. Москве состоялось заседание консультационного совета, посвященного вопросам применения иммуннотерапии у пациентов с местно-распространенным или метастатическим уротелиальным раком, ранее не получавших лечения или перенесших химиотерапию с включением препаратов платины, а также получавших неоадъювантную или адъювантную химиотерапию в периоперационном периоде.

1. von der Maase H., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77. DOI: 10.1200/JCO.2000.18.17.3068.von der Maase H., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77. DOI: 10.1200/JCO.2000.18.17.3068.2. von der Maase H., Sengelov L., Roberts J.T. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602–8. DOI: 10.1200/JCO.2005.07.757.von der Maase H., Sengelov L., Roberts J.T. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602–8. DOI: 10.1200/JCO.2005.07.757.3. De Santi M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/ vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30(2):191–9. DOI: 10.1200/JCO.2011.37.3571.De Santi M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/ vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30(2):191–9. DOI: 10.1200/JCO.2011.37.3571.4. Raggi D., Miceli R., Sonpavde G. et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 2016;27(2):49–61. DOI: 10.1093/annonc/mdv509.Raggi D., Miceli R., Sonpavde G. et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 2016;27(2):49–61. DOI: 10.1093/annonc/mdv509.5. Balar A.V. IMvigor210, ASCO 2018. Abstract 4523; poster 349.Balar A.V. IMvigor210, ASCO 2018. Abstract 4523; poster 349.6. Merseburger A.S. EAU 2019, Plenary Session – Plenary Session 5 BN: Breaking news session.Merseburger A.S. EAU 2019, Plenary Session – Plenary Session 5 BN: Breaking news session.7. Powles T. et al. EAS 2017, IMvigor211.Powles T. et al. EAS 2017, IMvigor211.8. Balar A.V. ASCO-GU 2019. Abstract 394.Balar A.V. ASCO-GU 2019. Abstract 394.9. Wang Y., Zhou S., Yang F. et al. Treatmentrelated adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 2019. DOI: 10.1001/jamaoncol.2019.0393.Wang Y., Zhou S., Yang F. et al. Treatmentrelated adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 2019. DOI: 10.1001/jamaoncol.2019.0393.10. NCCN Guidelines for Bladder Cancer 03; 2019.NCCN Guidelines for Bladder Cancer 03; 2019.11. Boyd Z. CRI-CIMT-EATI-AACR 2015. Abstract B001.Boyd Z. CRI-CIMT-EATI-AACR 2015. Abstract B001.12. Petrylak D.P. ASCO 2015.Petrylak D.P. ASCO 2015.